Syndecan-1 Levels in Females with Active Rheumatoid Arthritis

• Published in: Journal of clinical medicine Vol. 13; no. 14; p. 4110
• Main Authors: Rodriguez-Jimenez, Norma Alejandra, Gonzalez-Ponce, Fabiola, Gamez-Nava, Jorge Ivan, Ramirez-Villafaña, Melissa, Saldaña-Cruz, Ana Miriam, Ponce-Guarneros, Juan Manuel, Olivas-Flores, Eva Maria, Macías-Islas, Miguel Angel, Valdivia-Tangarife, Edgar Ricardo, Jacobo-Cuevas, Heriberto, Ramos-Estrada, Luz Gabriela, Totsuka-Sutto, Sylvia, Cardona-Muñoz, Ernesto German, Gonzalez-Lopez, Laura, On Behalf Of The Group For The Assessment Of Prognosis Biomarkers In Autoimmune Disorders
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.07.2024
• Subjects: Angiogenesis; Cell adhesion & migration; disease activity; Drugs; Ethics; Growth factors; Heparan sulfate; Inflammation; Kinases; Leukocytes; Patients; Proteins; Rheumatoid arthritis; Rheumatology; syndecan-1; Womens health; disease activity; rheumatoid arthritis; syndecan-1
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13144110

The relationship between serum glycoprotein syndecan-1 and disease activity in rheumatoid arthritis (RA) is still unknown. This study aimed to evaluate whether serum syndecan-1 concentrations are associated with moderate/severe disease activity. Study Design: This was a cross-sectional study. Seventy-five adult women with RA were classified into (a) moderate/severe RA based on the disease activity score, using the erythrocyte sedimentation rate (DAS28-ESR ≥ 3.2, = 50), and (b) RA in remission (DAS28-ESR < 2.6, n = 25). Twenty-five healthy women were taken as the reference group. Syndecan-1 levels were determined using enzyme-linked immunosorbent assay (ELISA). High values of serum syndecan-1 levels (≥24 ng/mL) were used to identify the utility values of this biomarker. The patients with RA had higher levels of syndecan-1 than the controls ( < 0.001). RA patients with active disease had higher syndecan-1 levels than RA patients in remission (57.6 vs. 23.5 ng/mL, respectively; = 0.002). High syndecan-1 concentrations demonstrated the following utility values for identifying disease activity: sensitivity, 84% (95%CI: 71-93); specificity, 52% (95%CI: 31-72); positive predictive value, 78% (95%CI: 70-84); and negative predictive value, 62% (95%CI: 44-77). High syndecan-1 levels have good sensitivity and positive predictive value for identifying disease activity; however, their specificity is limited. Future prospective studies are needed to assess whether syndecan-1 levels can predict treatment failure in RA.